Preferred Label : CDK4/6 Inhibitor SPH4336;
NCIt related terms : SPH-4336;
NCIt definition : An orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types
4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration,
CDK4/6 inhibitor SPH4336 selectively targets and inhibits the activity of CDK4 and
CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the
G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest.
This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6
are serine/threonine kinases that are upregulated in many tumor cell types and play
a key role in the regulation of both cell cycle progression from the G1-phase into
the S-phase and tumor cell proliferation.;
UNII : 9X8U786V5T;
CAS number : 2765997-88-2;
Molecule name : SPH 4336; SPH-4336;
NCI Metathesaurus CUI : CL1912865;
Origin ID : C192804;
UMLS CUI : C5785427;
Semantic type(s)
- concept_is_in_subset
- has_target
